Although the standard first-line approach in patients with advanced, KRAS mutation-positive NSCLC is based on ICI, with or without platinum-based CT [52,53], a greater concern rises regarding the effectiveness of ICI alone in this set of patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.